Home World News EMA Recommends Granting a Marketing Authorisation for Generic Trabectedin World News EMA Recommends Granting a Marketing Authorisation for Generic Trabectedin By Ogkologos - April 30, 2025 583 0 Facebook Twitter Google+ Pinterest WhatsApp Trabectedin Accord is a generic of Yondelis, which has been authorised in the EU since 2007 Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Selumetinib Approved by FDA to Treat Children with NF1 April 14, 2020 Datopotamab Deruxtecan Shows Promising Activity in Heavily Pretreated Advanced HR-positive/HER2-negative and... May 7, 2024 Childhood cancer survivors at greater risk of ill health November 22, 2021 Genetic Cancer Screenings in Younger Women May Be Cost-Effective and Lead... November 26, 2020 Load more HOT NEWS Smoking Initiation Shifting from Teens to Young Adults What to Know About At-Home DNA Tests for Detecting Cancer Risk Cancer in My Community: Striving to Lead People to Cancer Care... Cancer Survivors Face High Rates of Housing Insecurity
